Hypertension prevalence in the All of Us Research Program among groups traditionally underrepresented in medical research.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 06 2021
Historique:
received: 09 11 2020
accepted: 04 06 2021
entrez: 23 6 2021
pubmed: 24 6 2021
medline: 28 10 2021
Statut: epublish

Résumé

The All of Us Research Program was designed to enable broad-based precision medicine research in a cohort of unprecedented scale and diversity. Hypertension (HTN) is a major public health concern. The validity of HTN data and definition of hypertension cases in the All of Us (AoU) Research Program for use in rule-based algorithms is unknown. In this cross-sectional, population-based study, we compare HTN prevalence in the AoU Research Program to HTN prevalence in the 2015-2016 National Health and Nutrition Examination Survey (NHANES). We used AoU baseline data from patient (age ≥ 18) measurements (PM), surveys, and electronic health record (EHR) blood pressure measurements. We retrospectively examined the prevalence of HTN in the EHR cohort using Systemized Nomenclature of Medicine (SNOMED) codes and blood pressure medications recorded in the EHR. We defined HTN as the participant having at least 2 HTN diagnosis/billing codes on separate dates in the EHR data AND at least one HTN medication. We calculated an age-standardized HTN prevalence according to the age distribution of the U.S. Census, using 3 groups (18-39, 40-59, and ≥ 60). Among the 185,770 participants enrolled in the AoU Cohort (mean age at enrollment = 51.2 years) available in a Researcher Workbench as of October 2019, EHR data was available for at least one SNOMED code from 112,805 participants, medications for 104,230 participants, and 103,490 participants had both medication and SNOMED data. The total number of persons with SNOMED codes on at least two distinct dates and at least one antihypertensive medication was 33,310 for a crude prevalence of HTN of 32.2%. AoU age-adjusted HTN prevalence was 27.9% using 3 groups compared to 29.6% in NHANES. The AoU cohort is a growing source of diverse longitudinal data to study hypertension nationwide and develop precision rule-based algorithms for use in hypertension treatment and prevention research. The prevalence of hypertension in this cohort is similar to that in prior population-based surveys.

Identifiants

pubmed: 34158555
doi: 10.1038/s41598-021-92143-w
pii: 10.1038/s41598-021-92143-w
pmc: PMC8219813
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

12849

Subventions

Organisme : NIH HHS
ID : OT2 OD025276
Pays : United States
Organisme : NIH HHS
ID : OT2 OD025337
Pays : United States
Organisme : NIH HHS
ID : OT2 OD026553
Pays : United States
Organisme : NIH HHS
ID : OT2 OD026548
Pays : United States
Organisme : NIH HHS
ID : OT2 OD023206
Pays : United States
Organisme : NIH HHS
ID : OT2 OD026552
Pays : United States
Organisme : NIH HHS
ID : OT2 OD026549
Pays : United States
Organisme : NIH HHS
ID : OT2 OD026557
Pays : United States
Organisme : NIH HHS
ID : OT2 OD026554
Pays : United States
Organisme : NIH HHS
ID : OT2 OD023205
Pays : United States
Organisme : NIH HHS
ID : OT2 OD025315
Pays : United States
Organisme : NIH HHS
ID : OT2 OD026550
Pays : United States
Organisme : NIH HHS
ID : OT2 OD026555
Pays : United States
Organisme : NIH HHS
ID : OT2 OD025277
Pays : United States
Organisme : NIH HHS
ID : U24 OD023121
Pays : United States
Organisme : NIH HHS
ID : U2C OD023196
Pays : United States
Organisme : NIH HHS
ID : OT2 OD026556
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES030285
Pays : United States
Organisme : NIH HHS
ID : U24 OD023176
Pays : United States
Organisme : NIH HHS
ID : OT2 OD026551
Pays : United States
Organisme : NIH HHS
ID : U24 OD023163
Pays : United States

Investigateurs

Habibul Ahsan (H)
Toluwalase Ajayi (T)
Alvaro Alonso (A)
Amit Arora (A)
Briseis Aschebrook-Kilfoy (B)
Sally L Baxter (SL)
Dean Billheimer (D)
Eugene R Bleeker (ER)
Luca Bonomi (L)
Olveen Carrasquillo (O)
Qingxia Chen (Q)
Dave Chesla (D)
Andrew Craver (A)
Zubin Dastur (Z)
The Pride Study/PRIDEnet (TP)
John Ehiri (J)
Mara M Epstein (MM)
Xiaoke Feng (X)
Annesa Flentje (A)
Alliance Health Project (AH)
Lawrence Garber (L)
Nicholas Giangreco (N)
Yi Guo (Y)
Robert A Hiatt (RA)
Kai Yin Ho (KY)
Joyce Ho (J)
William Hogan (W)
George Hripcsak (G)
Carolyn Hunt (C)
Rosario Isai (R)
Xinzhuo Jiang (X)
Christine C Johnson (CC)
King Jordan (K)
Christine Lm Joseph (CL)
Hooman Kamel (H)
Jason H Kames (JH)
Theresa H Keegan (TH)
Karen Kim (K)
Katherine K Kim (KK)
Jihoon Kim (J)
Paula King (P)
Yann C Klimentidis (YC)
Irving L Kron (IL)
Tsung-Ting Kuo (TT)
Helen Lam (H)
James P Lash (JP)
Micah E Lubensky (ME)
Mitchell R Lunn (MR)
Yves A Lussier (YA)
Jacob L McCauley (JL)
Robert Meller (R)
Deborah A Meyers (DA)
Raul A Montanex Valverde (RA)
Julia L Moore Vogel (JLM)
Shashwat D Nagar (SD)
Kartnik Natarajan (K)
Juno Obedin-Maliver (J)
Paulina Paul (P)
Pamela A Pawloski (PA)
Cathryn Peltz-Rauchman (C)
Priscilla Pemu (P)
Fomessa T Randal (FT)
Ana Rescate (A)
Ana C Ricardo (AC)
M Elizabeth Ross (ME)
Brittney Roth-Manning (B)
Madhi Saranadasa (M)
Ning Shang (N)
Emily G Spencer (EG)
Cassie Springer (C)
Alan Stevens (A)
Vignesh Subbian (V)
Amy Tang (A)
Rhonda K Trousdale (RK)
Jill Waalen (J)
Stephen Waring (S)
Chunhua Weng (C)
Lisa White (L)
Sonya White (S)
Nathan E Wineinger (NE)
Chen Yeh (C)
Hsueh-Han Yeh (HH)
Paul Zakin (P)
Yanhua Zhos (Y)
Stephan Zuchner (S)
Robert Cronin (R)
Alese Halvorson (A)
Brian Ahmedani (B)

Références

JAMA Netw Open. 2020 Mar 2;3(3):e200255
pubmed: 32119093
Hypertension. 2009 Dec;54(6):1423-8
pubmed: 19858407
JAMA. 2018 Nov 6;320(17):1751-1752
pubmed: 30398610
N Engl J Med. 2019 Nov 7;381(19):1884
pubmed: 31693825
Lancet. 2019 Aug 24;394(10199):652-662
pubmed: 31327566
Acta Diabetol. 2021 Feb;58(2):215-220
pubmed: 33047257
Can J Cardiol. 2017 Aug;33(8):1052-1059
pubmed: 28754391
N Engl J Med. 2020 Aug 27;383(9):874-882
pubmed: 32853499
Am J Hypertens. 2020 Nov 3;33(11):967-974
pubmed: 32615586
N Engl J Med. 2019 Aug 15;381(7):668-676
pubmed: 31412182
JMIR Mhealth Uhealth. 2020 Oct 19;8(10):e21759
pubmed: 33074161
JAMA. 2003 Apr 23-30;289(16):2083-93
pubmed: 12709466
Ann Emerg Med. 2008 Apr;51(4):426-32
pubmed: 17583378
Eur Cardiol. 2019 Jul 11;14(2):111-115
pubmed: 31360232
Curr Hypertens Rep. 2020 Aug 27;22(9):70
pubmed: 32852654
J Hypertens. 2015 Feb;33(2):221-9
pubmed: 25479029
J Cardiovasc Pharmacol Ther. 2019 May;24(3):207-214
pubmed: 30563358
NPJ Digit Med. 2020 Feb 6;3:17
pubmed: 32047862
J Am Med Inform Assoc. 2016 Apr;23(e1):e20-7
pubmed: 26338219
J Public Health (Oxf). 2016 Sep;38(3):e392-e399
pubmed: 26547088
N Engl J Med. 1997 Apr 17;336(16):1117-24
pubmed: 9099655
Age Ageing. 2021 May 5;50(3):980-984
pubmed: 33068100
Circulation. 2010 Feb 2;121(4):586-613
pubmed: 20089546
Am J Phys Anthropol. 2017 May;163(1):122-128
pubmed: 28198537
NCHS Data Brief. 2017 Oct;(289):1-8
pubmed: 29155682
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
JAMA. 2017 Dec 5;318(21):2073-2074
pubmed: 29159375
PLoS One. 2017 Feb 21;12(2):e0171745
pubmed: 28222112
Circ Cardiovasc Qual Outcomes. 2012 May;5(3):343-51
pubmed: 22550130
Endocrine. 2019 Dec;66(3):456-459
pubmed: 31410748
JAMA. 2020 Sep 22;324(12):1190-1200
pubmed: 32902588
LGBT Health. 2014 Mar 13;1(2):131-139
pubmed: 25364769

Auteurs

Paulette D Chandler (PD)

Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. pchandler@bwh.harvard.edu.

Cheryl R Clark (CR)

Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Guohai Zhou (G)

Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Nyia L Noel (NL)

Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.

Confidence Achilike (C)

Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.

Lizette Mendez (L)

Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.

Andrea H Ramirez (AH)

Vanderbilt University Medical Center, Nashville, TN, USA.

Roxana Loperena-Cortes (R)

Vanderbilt University Medical Center, Nashville, TN, USA.

Kelsey Mayo (K)

Vanderbilt University Medical Center, Nashville, TN, USA.

Elizabeth Cohn (E)

Hunter College, New York, NY, USA.

Lucila Ohno-Machado (L)

University of California, San Diego, CA, USA.

Eric Boerwinkle (E)

University of Texas Health Science Center School of Public Health, Houston, TX, USA.

Mine Cicek (M)

Mayo Clinic, Rochester, MN, USA.

Jun Qian (J)

Vanderbilt University Medical Center, Nashville, TN, USA.

Sheri Schully (S)

National Institutes of Health, Bethesda, MD, USA.

Francis Ratsimbazafy (F)

Vanderbilt University Medical Center, Nashville, TN, USA.

Stephen Mockrin (S)

Life Sciences Division, Leidos, Inc, Frederick, MD, USA.

Kelly Gebo (K)

Johns Hopkins University, Baltimore, MD, USA.

Julien J Dedier (JJ)

Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.

Shawn N Murphy (SN)

Research Information Science and Computing, Mass General Brigham, Boston, MA, USA.

Jordan W Smoller (JW)

Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.

Elizabeth W Karlson (EW)

Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH